Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

An α-Acetoxy-Tirucallic Acid Isomer Inhibits Akt/mTOR Signaling and Induces Oxidative Stress in Prostate Cancer Cells

Menna El Gaafary, Berthold Büchele, Tatiana Syrovets, Sara Agnolet, Bernd Schneider, Christoph Q. Schmidt and Thomas Simmet
Journal of Pharmacology and Experimental Therapeutics January 2015, 352 (1) 33-42; DOI: https://doi.org/10.1124/jpet.114.217323
Menna El Gaafary
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berthold Büchele
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Syrovets
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Agnolet
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Schneider
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Q. Schmidt
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Simmet
Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany (M.E.G., B.B., Ta.S., C.Q.S., Th.S.); and Max Planck Institute for Chemical Ecology, Research Group Biosynthesis/NMR, Jena, Germany (S.A., B.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Here we provide evidence that αATA(8,24) (3α-acetyloxy-tir-8,24-dien-21-oic acid) inhibits Akt/mammalian target of rapamycin (mTOR) signaling. αATA(8,24) and other tirucallic acids were isolated from the acetylated extract of the oleo gum resin of Boswellia serrata to chemical homogeneity. Compared with related tirucallic acids, αATA(8,24) was the most potent inhibitor of the proliferation of androgen-insensitive prostate cancer cells in vitro and in vivo, in prostate cancer xenografted onto chick chorioallantoic membranes. αATA(8,24) induced loss of cell membrane asymmetry, caspase-3 activation, and DNA fragmentation in vitro and in vivo. These effects were selective for cancer cells, because αATA(8,24) exerted no overt toxic effects on peripheral blood mononuclear cells or the chick embryo. At the molecular level, αATA(8,24) inhibited the Akt1 kinase activity. Prior to all biochemical signs of cellular dysfunction, αATA(8,24) induced inhibition of the Akt downstream target mTOR as indicated by dephosphorylation of S6K1. This event was followed by decreased expression of cell cycle regulators, such as cyclin D1, cyclin E, and cyclin B1, as well as cyclin-dependent kinases CDK4 and CDK2 and phosphoretinoblastoma protein, which led to inhibition of the cell-cycle progression. In agreement with the mTOR inhibition, αATA(8,24) and rapamycin increased the volume of acidic vesicular organelles. In contrast to rapamycin, αATA(8,24) destabilized lysosomal and mitochondrial membranes and induced reactive oxygen species production in cancer cells. The ability of αATA(8,24) to inhibit Akt/mTOR signaling and to induce simultaneously oxidative stress could be exploited for the development of novel antitumor therapeutics with a lower profile of toxic side effects.

Footnotes

    • Received June 6, 2014.
    • Accepted September 10, 2014.
  • M.E.G. was supported by the German Academic Exchange Service, DAAD.

  • dx.doi.org/10.1124/jpet.114.217323.

  • ↵Embedded ImageThis article has supplemental material available at jpet.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 352 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 352, Issue 1
1 Jan 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An α-Acetoxy-Tirucallic Acid Isomer Inhibits Akt/mTOR Signaling and Induces Oxidative Stress in Prostate Cancer Cells
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Acetoxy-Tirucallic Acid Inhibits Akt/mTOR Signaling

Menna El Gaafary, Berthold Büchele, Tatiana Syrovets, Sara Agnolet, Bernd Schneider, Christoph Q. Schmidt and Thomas Simmet
Journal of Pharmacology and Experimental Therapeutics January 1, 2015, 352 (1) 33-42; DOI: https://doi.org/10.1124/jpet.114.217323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleDrug Discovery and Translational Medicine

Acetoxy-Tirucallic Acid Inhibits Akt/mTOR Signaling

Menna El Gaafary, Berthold Büchele, Tatiana Syrovets, Sara Agnolet, Bernd Schneider, Christoph Q. Schmidt and Thomas Simmet
Journal of Pharmacology and Experimental Therapeutics January 1, 2015, 352 (1) 33-42; DOI: https://doi.org/10.1124/jpet.114.217323
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cx43 Activity and Modulation in the Myometrium
  • IKCa channels in muscle hypertrophy
  • Cellular impedance assay to predict human TRPV4 inhibition
Show more Drug Discovery and Translational Medicine

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics